Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-3989 plus nucleos(t)ide analog for hepatitis B/hepatitis D virus coinfection
2020-001249-37Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis D (HDV) and hepatitis B (HBV) comparing JNJ-3989 + nucleos(t)ide analog with Placebo + nucleos(t)ide analog (2 arms). Primary endpoint: Composite virologic and biochemical response at Week 48. Started Sep 2020; status: active.
02
Drugs
tomligisiran
03
Conditions
hepatitis D (HDV)hepatitis B (HBV)
Beyond the preview
Go deeper on 2020-001249-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001249-37.